Harold J. Burstein, MD, PhD

Harold J. Burstein, MD, PhD

Medical Oncology

Contact Information

Office Phone Number

617-632-3800

Fax

617-632-1930

Appointments

617-632-2175 (new patients)
617-632-3800 (established patients)

Biography

Harold J. Burstein, MD, PhD

Dr. Burstein graduated from Harvard College before earning his MD at Harvard Medical School. He also received a PhD in cellular immunology and a master's degree in the history of science from Harvard. He trained in internal medicine at Massachusetts General Hospital before his oncology fellowship at DFCI. In 1999, he joined the staff of DFCI and Brigham and Women's Hospital, where he is a clinician and clinical investigator in the Breast Oncology Center.  Dr. Burstein is an internationally renowned breast cancer expert, who has led and participated in multiple clinical trials, and developed national and international breast cancer treatment guidelines.  Recognized as one of the leading breast oncologists, he is a perennial "Top Doctor" in the US for breast cancer care.  He teaches students, residents and fellows at Harvard Medical School and Dana-Farber.

Researcher

Physician

Institute Physician
Professor of Medicine, Harvard Medical School

Centers/Programs

Diseases Treated

Board Certification

  • Internal Medicine, 1997
  • Medical Oncology, 2000

Fellowship

  • Dana-Farber Cancer Institute, Hematology/Oncology

Residency

  • Massachusetts General Hospital, Internal Medicine

Medical School

  • Harvard Medical School

Recent Awards

  • George P. Canellos Award for Excellence in Clinical Investigation and Patient Care 2001
  • Fellow of the American Society of Clinical Oncology, 2012
  • Dana-Farber Cancer Institute Clinical Mentor Award, 2014

Research

    Clinical Investigation of Breast Cancer

    In the Breast Oncology Center, our clinical trials help define new treatment options for women with early-stage and advanced breast cancer. These trials use the scientific and laboratory resources at the Dana-Farber/Harvard Cancer Center to translate clinical observations into well-described biological phenomena. Some of our recent studies are described below.We have conducted several NCI-supported phase II trials of angiogenesis inhibitors in advanced breast cancer. These studies analyzed clinical outcomes for treatment with standard or low-dose "metronomic" chemotherapy (also thought to have anti-angiogenic potential) in combination with bevacizumab, an anti-vascular endothelial growth factor (VEGF) antibody. The primary endpoints of these studies are to characterize the response rate and safety profile of treatments. Correlative studies are analyzing baseline and dynamic measures of angiogenesis as predictors of tumor response, including measurement of circulating endothelial cells. Based on encouraging preliminary findings for these trials, we developed a trial of bevacizumab and metronomic chemotherapy that is now open to patients with early-stage breast cancer. This study will also use proteomics to gauge the extent of anti-angiogenic activity.In addition, we are evaluating other novel agents in clinical trials, including various anti-angiogenesis drugs and new formulations of chemotherapy and hormonal therapy.With colleagues in the health services research division at Dana-Farber, we are also exploring optimal use of adjuvant endocrine therapy for breast cancer. In these research efforts, we use computer modeling to help define which treatment strategies (e.g., tamoxifen, an aromatase inhibitor, or sequential treatment with one and then the other) would best prevent cancer recurrence. Such outcomes analyses can help inform clinical decision when direct data are not available to guide recommendations.

    Publications

      • ASO Visual Abstract: Defining the Biology of Estrogen Receptor-Low Positive Breast Cancer. Ann Surg Oncol. 2024 Apr; 31(4):2284-2285. View in: Pubmed

      • Defining the Biology of Estrogen Receptor-Low-Positive Breast Cancer. Ann Surg Oncol. 2024 Apr; 31(4):2244-2252. View in: Pubmed

      • Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2024 Feb; 35(2):159-182. View in: Pubmed

      • A randomized phase II study of metronomic cyclophosphamide and methotrexate (CM) with or without bevacizumab in patients with advanced breast cancer. Breast Cancer Res Treat. 2024 Feb; 204(1):123-132. View in: Pubmed

      • Understanding breast cancer complexity to improve patient outcomes: The St Gallen International Consensus Conference for the Primary Therapy of Individuals with Early Breast Cancer 2023. Ann Oncol. 2023 11; 34(11):970-986. View in: Pubmed

      • Circulating tumor DNA association with residual cancer burden after neoadjuvant chemotherapy in triple-negative breast cancer in TBCRC 030. Ann Oncol. 2023 10; 34(10):899-906. View in: Pubmed

      • Impact of BMI in Patients With Early Hormone Receptor-Positive Breast Cancer Receiving Endocrine Therapy With or Without Palbociclib in the PALLAS Trial. J Clin Oncol. 2023 Nov 20; 41(33):5118-5130. View in: Pubmed

      • Clonal hematopoiesis in older patients with breast cancer receiving chemotherapy. J Natl Cancer Inst. 2023 08 08; 115(8):981-988. View in: Pubmed

      • NCCN Guidelines® Insights: Breast Cancer, Version 4.2023. J Natl Compr Canc Netw. 2023 06; 21(6):594-608. View in: Pubmed

      • ESMO expert consensus statements (ECS) on the definition, diagnosis, and management of HER2-low breast cancer. Ann Oncol. 2023 08; 34(8):645-659. View in: Pubmed

      • Testing for ESR1 Mutations to Guide Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: ASCO Guideline Rapid Recommendation Update. J Clin Oncol. 2023 06 20; 41(18):3423-3425. View in: Pubmed

      • Identifying Patterns and Barriers in OncotypeDX Recurrence Score Testing in Older Patients With Early-Stage, Estrogen Receptor-Positive Breast Cancer: Implications for Guidance and Reimbursement. JCO Oncol Pract. 2023 08; 19(8):560-570. View in: Pubmed

      • The dilemma of selecting a first line CDK4/6 inhibitor for hormone receptor-positive/HER2-negative metastatic breast cancer. NPJ Breast Cancer. 2023 Mar 22; 9(1):15. View in: Pubmed

      • Circulating tumor DNA association with residual cancer burden after neoadjuvant chemotherapy in triple-negative breast cancer in TBCRC 030. medRxiv. 2023 Mar 08. View in: Pubmed

      • Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer: final 10-year analysis of the open-label, single-arm, phase 2 APT trial. Lancet Oncol. 2023 03; 24(3):273-285. View in: Pubmed

      • Escalation, De-escalation, Adaptation, Speciation, Customization: The New Approaches to Breast Cancer. Hematol Oncol Clin North Am. 2023 02; 37(1):xiii-xvi. View in: Pubmed

      • Adjuvant Exemestane With Ovarian Suppression in Premenopausal Breast Cancer: Long-Term Follow-Up of the Combined TEXT and SOFT Trials. J Clin Oncol. 2023 03 01; 41(7):1376-1382. View in: Pubmed

      • Adjuvant Endocrine Therapy in Premenopausal Breast Cancer: 12-Year Results From SOFT. J Clin Oncol. 2023 03 01; 41(7):1370-1375. View in: Pubmed

      • ASO Visual Abstract: Expanding Staging Criteria in T1-2N0 Hormone Receptor-Positive Breast Cancer Patients Enrolled in TAILORx. Ann Surg Oncol. 2022 Dec; 29(13):8024-8025. View in: Pubmed

      • Treatment discontinuation, patient-reported toxicities and quality-of-life by age following trastuzumab emtansine or paclitaxel/trastuzumab (ATEMPT). NPJ Breast Cancer. 2022 Nov 30; 8(1):127. View in: Pubmed

      • ASO Visual Abstract: Sentinel Lymph Node Biopsy Alone is Adequate for Chemotherapy Decisions in Postmenopausal Early-Stage, Hormone-Receptor-Positive, HER2-Negative Breast Cancer with 1-3 Positive Sentinel Lymph Nodes. Ann Surg Oncol. 2022 Nov; 29(12):7683-7684. View in: Pubmed

      • 'ADVANCE' (a pilot trial) ADjuVANt chemotherapy in the elderly: Developing and evaluating lower-toxicity chemotherapy options for older patients with breast cancer. J Geriatr Oncol. 2023 Jan; 14(1):101377. View in: Pubmed

      • Postneoadjuvant treatment for triple-negative breast cancer. Curr Opin Oncol. 2022 11 01; 34(6):623-634. View in: Pubmed

      • Expanding the Staging Criteria for T1-2N0 Hormone-Receptor Positive Breast Cancer Patients Enrolled in TAILORx. Ann Surg Oncol. 2022 Dec; 29(13):8016-8023. View in: Pubmed

      • Sentinel Lymph Node Biopsy Alone is Adequate for Chemotherapy Decisions in Postmenopausal Early-Stage Hormone-Receptor-Positive, HER2-Negative Breast Cancer with One to Three Positive Sentinel Lymph Nodes. Ann Surg Oncol. 2022 Nov; 29(12):7674-7682. View in: Pubmed

      • Breast Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2022 06; 20(6):691-722. View in: Pubmed

      • A look at current and potential treatment approaches for hormone receptor-positive, HER2-negative early breast cancer. Cancer. 2022 06 01; 128 Suppl 11:2209-2223. View in: Pubmed

      • Risk-adapted modulation through de-intensification of cancer treatments: an ESMO classification. Ann Oncol. 2022 07; 33(7):702-712. View in: Pubmed

      • Cardiac outcomes of subjects on adjuvant trastuzumab emtansine vs paclitaxel in combination with trastuzumab for stage I HER2-positive breast cancer (ATEMPT) study (TBCRC033): a randomized controlled trial. NPJ Breast Cancer. 2022 Feb 16; 8(1):18. View in: Pubmed

      • Treatment Exposure and Discontinuation in the PALbociclib CoLlaborative Adjuvant Study of Palbociclib With Adjuvant Endocrine Therapy for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer (PALLAS/AFT-05/ABCSG-42/BIG-14-03). J Clin Oncol. 2022 02 10; 40(5):449-458. View in: Pubmed

      • Local Therapy Outcomes and Toxicity From the ATEMPT Trial (TBCRC 033): A Phase II Randomized Trial of Adjuvant Trastuzumab Emtansine Versus Paclitaxel in Combination With Trastuzumab in Women With Stage I HER2-Positive Breast Cancer. Int J Radiat Oncol Biol Phys. 2022 05 01; 113(1):117-124. View in: Pubmed

      • Should Ki-67 be adopted to select breast cancer patients for treatment with adjuvant abemaciclib? Ann Oncol. 2022 03; 33(3):234-238. View in: Pubmed

      • Unmet challenges in systemic therapy for early stage breast cancer. Breast. 2022 Mar; 62 Suppl 1:S67-S69. View in: Pubmed

      • Expanding Criteria for Prognostic Stage IA in Hormone Receptor-Positive Breast Cancer. J Natl Cancer Inst. 2021 Nov 29; 113(12):1744-1750. View in: Pubmed

      • Prospective Study Testing a Simplified Paclitaxel Premedication Regimen in Patients with Early Breast Cancer. Oncologist. 2021 11; 26(11):927-933. View in: Pubmed

      • The Global Landscape of Treatment Standards for Breast Cancer. J Natl Cancer Inst. 2021 09 04; 113(9):1143-1155. View in: Pubmed

      • Continuous versus intermittent extended adjuvant letrozole for breast cancer: final results of randomized phase III SOLE (Study of Letrozole Extension) and SOLE Estrogen Substudy. Ann Oncol. 2021 10; 32(10):1256-1266. View in: Pubmed

      • Endocrine Treatment and Targeted Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: ASCO Guideline Update. J Clin Oncol. 2021 12 10; 39(35):3959-3977. View in: Pubmed

      • Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021. Ann Oncol. 2021 10; 32(10):1216-1235. View in: Pubmed

      • Chemotherapy-related amenorrhea (CRA) after adjuvant ado-trastuzumab emtansine (T-DM1) compared to paclitaxel in combination with trastuzumab (TH) (TBCRC033: ATEMPT Trial). Breast Cancer Res Treat. 2021 Aug; 189(1):103-110. View in: Pubmed

      • Adjuvant Trastuzumab Emtansine Versus Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT): A Randomized Clinical Trial. J Clin Oncol. 2021 07 20; 39(21):2375-2385. View in: Pubmed

      • NCCN Guidelines® Insights: Breast Cancer, Version 4.2021. J Natl Compr Canc Netw. 2021 05 01; 19(5):484-493. View in: Pubmed

      • NCCN Guidelines® Insights: Breast Cancer, Version 4.2021. J Natl Compr Canc Netw. 2021 05 01; 19(5):484-493. View in: Pubmed

      • Physical Activity, Weight, and Outcomes in Patients Receiving Chemotherapy for Metastatic Breast Cancer (C40502/Alliance). JNCI Cancer Spectr. 2021 06; 5(3). View in: Pubmed

      • Serial Analysis of Circulating Tumor Cells in Metastatic Breast Cancer Receiving First-Line Chemotherapy. J Natl Cancer Inst. 2021 04 06; 113(4):443-452. View in: Pubmed

      • Systemic Therapy for Estrogen Receptor-Positive, HER2-Negative Breast Cancer. Reply. N Engl J Med. 2021 03 25; 384(12):1176-1177. View in: Pubmed

      • Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 2021 02; 22(2):212-222. View in: Pubmed

      • Adjuvant Capecitabine in Triple-Negative Breast Cancer: New Strategies for Tailoring Treatment Recommendations. JAMA. 2021 01 05; 325(1):36-38. View in: Pubmed

      • Systemic Therapy for Estrogen Receptor-Positive, HER2-Negative Breast Cancer. N Engl J Med. 2020 12 24; 383(26):2557-2570. View in: Pubmed

      • A dynamic portrait of adverse events for breast cancer patients: results from a phase II clinical trial of eribulin in advanced HER2-negative breast cancer. Breast Cancer Res Treat. 2021 Jan; 185(1):135-144. View in: Pubmed

      • Multidisciplinary considerations in the treatment of triple-negative breast cancer. CA Cancer J Clin. 2020 11; 70(6):432-442. View in: Pubmed

      • Recommendations for prioritization, treatment, and triage of breast cancer patients during the COVID-19 pandemic. the COVID-19 pandemic breast cancer consortium. Breast Cancer Res Treat. 2020 Jun; 181(3):487-497. View in: Pubmed

      • Avoiding Peg-Filgrastim Prophylaxis During the Paclitaxel Portion of the Dose-Dense Doxorubicin-Cyclophosphamide and Paclitaxel Regimen: A Prospective Study. J Clin Oncol. 2020 07 20; 38(21):2390-2397. View in: Pubmed

      • Treatment-induced symptoms, depression and age as predictors of sexual problems in premenopausal women with early breast cancer receiving adjuvant endocrine therapy. Breast Cancer Res Treat. 2020 Jun; 181(2):347-359. View in: Pubmed

      • Breast Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2020 04; 18(4):452-478. View in: Pubmed

      • The legacy of Professor Aron Goldhirsch. Ann Oncol. 2020 06; 31(6):671-673. View in: Pubmed

      • Neoadjuvant treatment strategies for HER2-positive breast cancer: cost-effectiveness and quality of life outcomes. Breast Cancer Res Treat. 2020 May; 181(1):43-51. View in: Pubmed

      • Estimating the benefits of therapy for early-stage breast cancer: the St. Gallen International Consensus Guidelines for the primary therapy of early breast cancer 2019. Ann Oncol. 2019 Oct; 30(10):1541-1557. View in: Pubmed

      • A phase II feasibility study of palbociclib in combination with adjuvant endocrine therapy for hormone receptor-positive invasive breast carcinoma. Ann Oncol. 2019 Sep; 30(9):1514-1520. View in: Pubmed

      • Responses to subsequent anti-HER2 therapy after treatment with trastuzumab-DM1 in women with HER2-positive metastatic breast cancer. Ann Oncol. 2012 Jan; 23(1):93-97. View in: Pubmed

      • Corrections to "De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017". Ann Oncol. 2019 Jul; 30(7):1181. View in: Pubmed

      • Adjuvant endocrine therapy in postmenopausal women: making treatment choices based on the magnitude of benefit. Breast. 2019 Nov; 48 Suppl 1:S89-S91. View in: Pubmed

      • Estimating the benefits of therapy for early-stage breast cancer: the St. Gallen International Consensus Guidelines for the primary therapy of early breast cancer 2019. Ann Oncol. 2019 10 01; 30(10):1541-1557. View in: Pubmed

      • A phase II feasibility study of palbociclib in combination with adjuvant endocrine therapy for hormone receptor-positive invasive breast carcinoma. Ann Oncol. 2019 09 01; 30(9):1514-1520. View in: Pubmed

      • Randomized Trial of Standard Adjuvant Chemotherapy Regimens Versus Capecitabine in Older Women With Early Breast Cancer: 10-Year Update of the CALGB 49907 Trial. J Clin Oncol. 2019 09 10; 37(26):2338-2348. View in: Pubmed

      • De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017. Ann Oncol. 2019 07 01; 30(7):1181. View in: Pubmed

      • Impact of lapatinib plus trastuzumab versus single-agent lapatinib on quality of life of patients with trastuzumab-refractory HER2+ metastatic breast cancer. Ann Oncol. 2019 06 01; 30(6):1019. View in: Pubmed

      • Molecular Testing in Breast Cancer. Am Soc Clin Oncol Educ Book. 2019 Jan; 39:e1-e7. View in: Pubmed

      • Local-regional recurrence in women with small node-negative, HER2-positive breast cancer: results from a prospective multi-institutional study (the APT trial). Breast Cancer Res Treat. 2019 Jul; 176(2):303-310. View in: Pubmed

      • Seven-Year Follow-Up Analysis of Adjuvant Paclitaxel and Trastuzumab Trial for Node-Negative, Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer. J Clin Oncol. 2019 08 01; 37(22):1868-1875. View in: Pubmed

      • NCCN Guidelines Insights: Breast Cancer, Version 3.2018. J Natl Compr Canc Netw. 2019 02; 17(2):118-126. View in: Pubmed

      • A Breath-Taking Diagnosis. N Engl J Med. 2019 01 03; 380(1):81-87. View in: Pubmed

      • Adjuvant Endocrine Therapy for Women With Hormone Receptor-Positive Breast Cancer: ASCO Clinical Practice Guideline Focused Update. J Oncol Pract. 2019 Feb; 15(2):106-107. View in: Pubmed

      • Duration of adjuvant trastuzumab: might less be more? Ann Oncol. 2018 12 01; 29(12):2273-2274. View in: Pubmed

      • Adjuvant Endocrine Therapy for Women With Hormone Receptor-Positive Breast Cancer: ASCO Clinical Practice Guideline Focused Update. J Clin Oncol. 2019 02 10; 37(5):423-438. View in: Pubmed

      • Information Transparency in the Drug Approval Process. JAMA Oncol. 2018 11 01; 4(11):1621-1622. View in: Pubmed

      • De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017. Ann Oncol. 2018 Oct 01; 29(10):2153. View in: Pubmed

      • Functional Decline and Resilience in Older Women Receiving Adjuvant Chemotherapy for Breast Cancer. J Am Geriatr Soc. 2019 05; 67(5):920-927. View in: Pubmed

      • Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer. N Engl J Med. 2018 Jul 12; 379(2):122-137. View in: Pubmed

      • How Old is Too Old? Breast Cancer Treatment in Octogenarians. Ann Surg Oncol. 2018 06; 25(6):1458-1460. View in: Pubmed

      • Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2018 Mar; 16(3):310-320. View in: Pubmed

      • Clinical Cancer Advances 2018: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. J Clin Oncol. 2018 04 01; 36(10):1020-1044. View in: Pubmed

      • Reply to 'The St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2017: the point of view of an International Panel of Experts in Radiation Oncology' by Kirova et al. Ann Oncol. 2018 01 01; 29(1):281-282. View in: Pubmed

      • Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2018 01; 19(1):127-138. View in: Pubmed

      • De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017. Ann Oncol. 2017 08 01; 28(8):1700-1712. View in: Pubmed

      • Treatment Efficacy, Adherence, and Quality of Life Among Women Younger Than 35 Years in the International Breast Cancer Study Group TEXT and SOFT Adjuvant Endocrine Therapy Trials. J Clin Oncol. 2017 Sep 20; 35(27):3113-3122. View in: Pubmed

      • Blocking the Cycle: Cyclin-Dependent Kinase 4/6 Inhibitors in Metastatic, Hormone Receptor-Positive Breast Cancer. J Clin Oncol. 2017 Sep 01; 35(25):2866-2870. View in: Pubmed

      • NCCN Guidelines Insights: Breast Cancer, Version 1.2017. J Natl Compr Canc Netw. 2017 04; 15(4):433-451. View in: Pubmed

      • Clinical Cancer Advances 2017: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. J Clin Oncol. 2017 04 20; 35(12):1341-1367. View in: Pubmed

      • Experts' perspectives on the role of medical marijuana in oncology: A semistructured interview study. Psychooncology. 2017 08; 26(8):1087-1092. View in: Pubmed

      • Biosimilar Therapy for ERBB2 (HER2)-Positive Breast Cancer: Close Enough? JAMA. 2017 01 03; 317(1):30-32. View in: Pubmed

      • Optimizing Adjuvant Chemotherapy and Surgery for Early- and Late-Stage Breast Cancer. JAMA Oncol. 2016 Nov 01; 2(11):1399-1400. View in: Pubmed

      • Breast conservation following neoadjuvant therapy for breast cancer in the modern era: Are we losing the opportunity? Eur J Surg Oncol. 2016 Dec; 42(12):1780-1786. View in: Pubmed

      • Impact of neoadjuvant therapy on eligibility for and frequency of breast conservation in stage II-III HER2-positive breast cancer: surgical results of CALGB 40601 (Alliance). Breast Cancer Res Treat. 2016 11; 160(2):297-304. View in: Pubmed

      • Chemotherapy for Triple-Negative Breast Cancer: Is More Better? J Clin Oncol. 2016 10 01; 34(28):3369-71. View in: Pubmed

      • Treatment of early-stage human epidermal growth factor 2-positive cancers among medicare enrollees: age and race strongly associated with non-use of trastuzumab. Breast Cancer Res Treat. 2016 08; 159(1):151-62. View in: Pubmed

      • Endocrine Therapy for Hormone Receptor Positive Metastatic Breast Cancer: American Society of Clinical Oncology Guideline Summary. J Oncol Pract. 2016 Jun; 12(6):583-7. View in: Pubmed

      • Endocrine Therapy for Hormone Receptor-Positive Metastatic Breast Cancer: American Society of Clinical Oncology Guideline. J Clin Oncol. 2016 09 01; 34(25):3069-103. View in: Pubmed

      • Update in Hematology and Oncology: Evidence Published in 2015. Ann Intern Med. 2016 May 03; 164(9):W32-6. View in: Pubmed

      • Adjuvant Tamoxifen Plus Ovarian Function Suppression Versus Tamoxifen Alone in Premenopausal Women With Early Breast Cancer: Patient-Reported Outcomes in the Suppression of Ovarian Function Trial. J Clin Oncol. 2016 05 10; 34(14):1601-10. View in: Pubmed

      • Adjuvant Endocrine Therapy for Women With Hormone Receptor-Positive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update on Ovarian Suppression Summary. J Oncol Pract. 2016 Apr; 12(4):390-3. View in: Pubmed

      • Invasive Breast Cancer Version 1.2016, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2016 Mar; 14(3):324-54. View in: Pubmed

      • Adjuvant Endocrine Therapy for Women With Hormone Receptor-Positive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update on Ovarian Suppression. J Clin Oncol. 2016 05 10; 34(14):1689-701. View in: Pubmed

      • Cardiac Outcomes of Patients Receiving Adjuvant Weekly Paclitaxel and Trastuzumab for Node-Negative, ERBB2-Positive Breast Cancer. JAMA Oncol. 2016 Jan; 2(1):29-36. View in: Pubmed

      • NCCN Guidelines Insights Breast Cancer, Version 1.2016. J Natl Compr Canc Netw. 2015 Dec; 13(12):1475-85. View in: Pubmed

      • With better adjuvant therapy, does breast cancer stage still matter? BMJ. 2015 Oct 06; 351:h5273. View in: Pubmed

      • Adjuvant endocrine therapy for postmenopausal women: Type and duration. Breast. 2015 Nov; 24 Suppl 2:S126-8. View in: Pubmed

      • Postmenopausal breast cancer: a best endocrine strategy? Lancet. 2015 Oct 03; 386(10001):1317-1319. View in: Pubmed

      • Nodal Irradiation after Breast-Cancer Surgery in the Era of Effective Adjuvant Therapy. N Engl J Med. 2015 Jul 23; 373(4):379-81. View in: Pubmed

      • Patient-reported outcomes with adjuvant exemestane versus tamoxifen in premenopausal women with early breast cancer undergoing ovarian suppression (TEXT and SOFT): a combined analysis of two phase 3 randomised trials. Lancet Oncol. 2015 Jul; 16(7):848-58. View in: Pubmed

      • Chemotherapy-related amenorrhea after adjuvant paclitaxel-trastuzumab (APT trial). Breast Cancer Res Treat. 2015 Jun; 151(3):589-96. View in: Pubmed

      • Choosing Treatments on the Basis of Cost: Can Clinicians Opt for Less Expensive Treatments? J Oncol Pract. 2015 Jul; 11(4):322-4. View in: Pubmed

      • Breast Cancer Version 2.2015. J Natl Compr Canc Netw. 2015 Apr; 13(4):448-75. View in: Pubmed

      • Clinical cancer advances 2015: Annual report on progress against cancer from the American Society of Clinical Oncology. J Clin Oncol. 2015 Mar 01; 33(7):786-809. View in: Pubmed

      • Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer. N Engl J Med. 2015 Jan 08; 372(2):134-41. View in: Pubmed

      • Adjuvant ovarian suppression in premenopausal breast cancer. N Engl J Med. 2015 Jan 29; 372(5):436-46. View in: Pubmed

      • Endocrine therapy with or without inhibition of epidermal growth factor receptor and human epidermal growth factor receptor 2: a randomized, double-blind, placebo-controlled phase III trial of fulvestrant with or without lapatinib for postmenopausal women with hormone receptor-positive advanced breast cancer-CALGB 40302 (Alliance). J Clin Oncol. 2014 Dec 10; 32(35):3959-66. View in: Pubmed

      • Long-term follow-up after preoperative trastuzumab and chemotherapy for HER2-overexpressing breast cancer. Clin Breast Cancer. 2015 Feb; 15(1):24-30. View in: Pubmed

      • Randomized comparison of adjuvant aromatase inhibitor (AI) exemestane (E) plus ovarian function suppression (OFS) vs tamoxifen (T) plus OFS in premenopausal women with hormone receptor-positive (HR+) early breast cancer (BC): Joint analysis of IBCSG TEXT and SOFT trials. J Clin Oncol. 2014 Jun 20; 32(18_suppl):LBA1. View in: Pubmed

      • Comparison of doxorubicin and cyclophosphamide versus single-agent paclitaxel as adjuvant therapy for breast cancer in women with 0 to 3 positive axillary nodes: CALGB 40101 (Alliance). J Clin Oncol. 2014 Aug 01; 32(22):2311-7. View in: Pubmed

      • Outcomes by tumor subtype and treatment pattern in women with small, node-negative breast cancer: a multi-institutional study. J Clin Oncol. 2014 Jul 10; 32(20):2142-50. View in: Pubmed

      • Past, present, and future challenges in breast cancer treatment. J Clin Oncol. 2014 Jul 01; 32(19):1979-86. View in: Pubmed

      • Adjuvant exemestane with ovarian suppression in premenopausal breast cancer. N Engl J Med. 2014 Jul 10; 371(2):107-18. View in: Pubmed

      • Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: american society of clinical oncology clinical practice guideline focused update. J Clin Oncol. 2014 Jul 20; 32(21):2255-69. View in: Pubmed

      • Breast cancer version 3.2014. J Natl Compr Canc Netw. 2014 Apr; 12(4):542-90. View in: Pubmed

      • Sentinel lymph node biopsy for patients with early-stage breast cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2014 May 01; 32(13):1365-83. View in: Pubmed

      • Neoadjuvant pertuzumab: the exception that proves the rule? Oncology (Williston Park). 2014 Mar; 28(3):197-9. View in: Pubmed

      • Fifty years of systemic therapy for breast cancer: from one size fits all to tailored therapy. Am Soc Clin Oncol Educ Book. 2014; e1-3. View in: Pubmed

      • Use and duration of chemotherapy in patients with metastatic breast cancer according to tumor subtype and line of therapy. J Natl Compr Canc Netw. 2014 Jan; 12(1):71-80. View in: Pubmed

      • Trastuzumab: qui bono? J Natl Cancer Inst. 2013 Dec 04; 105(23):1772-5. View in: Pubmed

      • Personalized medicine in breast cancer: tamoxifen, endoxifen, and CYP2D6 in clinical practice. Breast Cancer Res Treat. 2013 Oct; 141(3):421-7. View in: Pubmed

      • Patients with triple negative breast cancer: is there an optimal adjuvant treatment? Breast. 2013 Aug; 22 Suppl 2:S147-8. View in: Pubmed

      • Clinicopathological features among patients with advanced human epidermal growth factor-2-positive breast cancer with prolonged clinical benefit to first-line trastuzumab-based therapy: a retrospective cohort study. Clin Breast Cancer. 2013 Aug; 13(4):254-63. View in: Pubmed

      • Lucky to be an oncologist. J Natl Compr Canc Netw. 2013 Aug; 11(8):909-10. View in: Pubmed

      • Expert opinion vs guideline based care: the St. Gallen Case study. Breast. 2013 Aug; 22 Suppl 2:S1-2. View in: Pubmed

      • Breast cancer, version 3.2013: featured updates to the NCCN guidelines. J Natl Compr Canc Netw. 2013 Jul; 11(7):753-60; quiz 761. View in: Pubmed

      • Breast cancer treatment in the era of individualized care. Hematol Oncol Clin North Am. 2013 Aug; 27(4):xiii-xv. View in: Pubmed

      • Lou Gehrig, Angelina Jolie, and cancer genetics. J Natl Compr Canc Netw. 2013 Jun 01; 11(6):631-2. View in: Pubmed

      • A phase II study of bevacizumab in combination with vinorelbine and trastuzumab in HER2-positive metastatic breast cancer. Breast Cancer Res Treat. 2013 Jun; 139(2):403-10. View in: Pubmed

      • Off-label use of oncology drugs: too much, too little, or just right? J Natl Compr Canc Netw. 2013 May 01; 11(5):505-6. View in: Pubmed

      • Keeping cancer patients out of the hospital at the end of life. J Natl Compr Canc Netw. 2013 Mar 01; 11(3):229-30. View in: Pubmed

      • High performance teamwork training and systems redesign in outpatient oncology. BMJ Qual Saf. 2013 May; 22(5):405-13. View in: Pubmed

      • Clinical outcomes and treatment practice patterns of patients with HER2-positive metastatic breast cancer in the post-trastuzumab era. Breast. 2013 Aug; 22(4):525-31. View in: Pubmed

      • Caring for breast cancer survivors. J Natl Compr Canc Netw. 2013 Jan 01; 11(1):1-2. View in: Pubmed

      • Implementation of team training in outpatient breast oncology. J Clin Oncol. 2012 Dec; 30(34_suppl):83. View in: Pubmed

      • Measuring hope: patient expectations of chemotherapy for advanced cancer. J Natl Compr Canc Netw. 2012 Dec 01; 10(12):1459-60. View in: Pubmed

      • A "shot heard 'round the world" on cancer drug costs? J Natl Compr Canc Netw. 2012 Nov 01; 10(11):1315-6. View in: Pubmed

      • Should response to preoperative chemotherapy affect radiotherapy recommendations after mastectomy for stage II breast cancer? J Clin Oncol. 2012 Nov 10; 30(32):3916-20. View in: Pubmed

      • Assuring access to academic cancer centers. J Natl Compr Canc Netw. 2012 Oct 01; 10(10):1177-8. View in: Pubmed

      • Combination antiangiogenic therapy in advanced breast cancer: a phase 1 trial of vandetanib, a VEGFR inhibitor, and metronomic chemotherapy, with correlative platelet proteomics. Breast Cancer Res Treat. 2012 Nov; 136(1):169-78. View in: Pubmed

      • Pathway-based oncology care: time for more transparency. J Natl Compr Canc Netw. 2012 Sep; 10(9):1043-4. View in: Pubmed

      • Making genuine progress against metastatic breast cancer. J Clin Oncol. 2012 Oct 01; 30(28):3448-51. View in: Pubmed

      • Adjuvant therapy in stage I carcinoma of the breast: the influence of multigene analyses and molecular phenotyping. Breast J. 2012 Jul-Aug; 18(4):303-11. View in: Pubmed

      • Simplifying guidelines: we only need one adjuvant chemotherapy regimen for breast cancer. J Natl Compr Canc Netw. 2012 Jul 01; 10(7):797-8. View in: Pubmed

      • Metastatic breast cancer, version 1.2012: featured updates to the NCCN guidelines. J Natl Compr Canc Netw. 2012 Jul 01; 10(7):821-9. View in: Pubmed

      • Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 Study. J Clin Oncol. 2012 Jul 20; 30(21):2585-92. View in: Pubmed

      • The top five in oncology: where do we go from here? J Natl Compr Canc Netw. 2012 Jun 01; 10(6):681-2. View in: Pubmed

      • Estimation of tamoxifen metabolite concentrations in the blood of breast cancer patients through CYP2D6 genotype activity score. Breast Cancer Res Treat. 2012 Jun; 133(2):677-83. View in: Pubmed

      • Choosing the best trastuzumab-based adjuvant chemotherapy regimen: should we abandon anthracyclines? J Clin Oncol. 2012 Jun 20; 30(18):2179-82. View in: Pubmed

      • If the choices are all the same, why not prefer the less-expensive option? J Natl Compr Canc Netw. 2012 Apr; 10(4):425-6. View in: Pubmed

      • Breast cancer: Neoadjuvant bevacizumab treatment-signal or noise? Nat Rev Clin Oncol. 2012 Mar 13; 9(4):191-2. View in: Pubmed

      • Patient advocates' role in clinical trials: perspectives from Cancer and Leukemia Group B investigators and advocates. Cancer. 2012 Oct 01; 118(19):4801-5. View in: Pubmed

      • Pre-judging data: benchmarking clinical significance before study results are known. J Natl Compr Canc Netw. 2012 Mar; 10(3):289-90. View in: Pubmed

      • Disclosing pharma payments to oncologists: what will we learn? J Natl Compr Canc Netw. 2012 Feb; 10(2):133-4. View in: Pubmed

      • Deep time: the long and the short of adjuvant endocrine therapy for breast cancer. J Clin Oncol. 2012 Mar 01; 30(7):684-6. View in: Pubmed

      • Update of the oxford overview: new insight and perspectives in the era of personalized medicine. Am Soc Clin Oncol Educ Book. 2012; 71-9. View in: Pubmed

      • JNCCN reaches 10. J Natl Compr Canc Netw. 2012 Jan; 10(1):3. View in: Pubmed

      • Avastin for breast cancer, 2005-2011: requiescat in pacem? J Natl Compr Canc Netw. 2011 Dec; 9(12):1321-3. View in: Pubmed

      • The continuity of care checklist: a critical frontier in patient safety. J Natl Compr Canc Netw. 2011 Nov; 9(11):1217-8. View in: Pubmed

      • Can axillary node dissection be omitted in a subset of patients with low local and regional failure rates? Breast J. 2012 Jan-Feb; 18(1):23-7. View in: Pubmed

      • Patients with anti-HER2 responsive disease: definition and adjuvant therapies. Breast. 2011 Oct; 20 Suppl 3:S132-4. View in: Pubmed

      • Have we been down this road before? J Natl Compr Canc Netw. 2011 Sep 01; 9(9):953. View in: Pubmed

      • Peek before you treat? Is it a fantasy or reality? J Oncol Pract. 2011 Sep; 7(5):338-9. View in: Pubmed

      • American Society of Clinical Oncology clinical practice guideline update on the use of chemotherapy sensitivity and resistance assays. J Clin Oncol. 2011 Aug 20; 29(24):3328-30. View in: Pubmed

      • The fifth "C" is cost: highlights from ASCO 2011. J Natl Compr Canc Netw. 2011 Jul 01; 9(7):691. View in: Pubmed

      • Radiation therapy for ductal carcinoma in situ: a decision analysis. Cancer. 2012 Feb 01; 118(3):603-11. View in: Pubmed

      • Surgery of the primary tumor does not improve survival in stage IV breast cancer. Breast Cancer Res Treat. 2011 Sep; 129(2):459-65. View in: Pubmed

      • CMF revisited in the 21st century. Ann Oncol. 2012 Feb; 23(2):305-11. View in: Pubmed

      • Introduction: Current and future approaches to chemotherapy in patients with resistant breast cancer. Semin Oncol. 2011 Jun; 38 Suppl 2:S1-2. View in: Pubmed

      • Novel agents and future directions for refractory breast cancer. Semin Oncol. 2011 Jun; 38 Suppl 2:S17-24. View in: Pubmed

      • Long-term outcomes after neoadjuvant trastuzumab and chemotherapy for HER2+ breast cancer. J Clin Oncol. 2011 May 20; 29(15_suppl):e11074. View in: Pubmed

      • Recent advances in the treatment of breast cancer: highlights from the 2010 San Antonio Breast Cancer Symposium. Clin Adv Hematol Oncol. 2011 May; 9(5 Suppl 11):1-16. View in: Pubmed

      • Texting the doctor. J Natl Compr Canc Netw. 2011 May; 9(5):459. View in: Pubmed

      • Responses to subsequent anti-HER2 therapy after treatment with trastuzumab-DM1 in women with HER2-positive metastatic breast cancer. Ann Oncol. 2012 Jan; 23(1):93-97. View in: Pubmed

      • Contrary effects of the receptor tyrosine kinase inhibitor vandetanib on constitutive and flow-stimulated nitric oxide elaboration in humans. Hypertension. 2011 Jul; 58(1):85-92. View in: Pubmed

      • Mind the gap. J Natl Compr Canc Netw. 2011 Apr; 9(4):343. View in: Pubmed

      • Impact of lapatinib plus trastuzumab versus single-agent lapatinib on quality of life of patients with trastuzumab-refractory HER2+ metastatic breast cancer. Ann Oncol. 2011 Dec; 22(12):2582-2590. View in: Pubmed

      • Bevacizumab for advanced breast cancer: all tied up with a RIBBON? J Clin Oncol. 2011 Apr 01; 29(10):1232-5. View in: Pubmed

      • EMBRACE, eribulin, and new realities of advanced breast cancer. Lancet. 2011 Mar 12; 377(9769):878-80. View in: Pubmed

      • Zoledronic acid preserves bone mineral density in premenopausal women who develop ovarian failure due to adjuvant chemotherapy: final results from CALGB trial 79809. Eur J Cancer. 2011 Mar; 47(5):683-9. View in: Pubmed

      • Take your medicine. J Natl Compr Canc Netw. 2011 Feb; 9 Suppl 3:S1. View in: Pubmed

      • Invasive breast cancer. J Natl Compr Canc Netw. 2011 Feb; 9(2):136-222. View in: Pubmed

      • Take Your Medicine J Natl Compr Canc Netw. 2011 Feb 01; 9(9 Suppl 3):S1. View in: Pubmed

      • Congestive heart failure risk in patients with breast cancer treated with bevacizumab. J Clin Oncol. 2011 Feb 20; 29(6):632-8. View in: Pubmed

      • Beaten at the Alamo by the Europeans. J Natl Compr Canc Netw. 2011 Jan; 9(1):1. View in: Pubmed

      • Board recertification. J Natl Compr Canc Netw. 2010 Oct; 8(10):1111. View in: Pubmed

      • Breast cancer: noninvasive and special situations. J Natl Compr Canc Netw. 2010 Oct; 8(10):1182-207. View in: Pubmed

      • Cardiac toxicity from systemic cancer therapy: a comprehensive review. Prog Cardiovasc Dis. 2010 Sep-Oct; 53(2):94-104. View in: Pubmed

      • Addressing oncology pharmacy & policy. J Natl Compr Canc Netw. 2010 Sep; 8 Suppl 7:S1. View in: Pubmed

      • American society of clinical oncology clinical practice guideline update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. J Oncol Pract. 2010 Sep; 6(5):243-6. View in: Pubmed

      • Avastin, ODAC, and the FDA: are we drafting the right players? J Natl Compr Canc Netw. 2010 Aug; 8(8):833-4. View in: Pubmed

      • American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. J Clin Oncol. 2010 Aug 10; 28(23):3784-96. View in: Pubmed

      • Adjuvant hormonal therapy for early-stage breast cancer. Surg Oncol Clin N Am. 2010 Jul; 19(3):639-47. View in: Pubmed

      • SABRE-B: an evaluation of paclitaxel and bevacizumab with or without sunitinib as first-line treatment of metastatic breast cancer. Ann Oncol. 2010 Dec; 21(12):2370-2376. View in: Pubmed

      • Re-engineering the cooperative groups. J Natl Compr Canc Netw. 2010 May; 8(5):505. View in: Pubmed

      • Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErbB2-positive breast cancer. J Clin Oncol. 2010 Mar 10; 28(8):1301-7. View in: Pubmed

      • Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. J Clin Oncol. 2010 Mar 01; 28(7):1124-30. View in: Pubmed

      • Refining therapy for human epidermal growth factor receptor 2-positive breast cancer: T stands for trastuzumab, tumor size, and treatment strategy. J Clin Oncol. 2009 Dec 01; 27(34):5671-3. View in: Pubmed

      • Screening contretemps: the real issue in the mammogram guideline debate. J Natl Compr Canc Netw. 2009 Nov; 7(10):1039-40. View in: Pubmed

      • Late effects of adjuvant systemic therapies in women diagnosed with breast cancer at a young age. Breast. 2009 Oct; 18 Suppl 3:S135-6. View in: Pubmed

      • What is a patient navigator, and should we have them in major cancer centers? J Natl Compr Canc Netw. 2009 Oct; 7(9):905. View in: Pubmed

      • NCCN Task Force Report: Estrogen Receptor and Progesterone Receptor Testing in Breast Cancer by Immunohistochemistry. J Natl Compr Canc Netw. 2009 Sep; 7 Suppl 6:S1-S21; quiz S22-3. View in: Pubmed

      • Colon cancer: the new breast cancer. J Natl Compr Canc Netw. 2009 Sep; 7(8):773. View in: Pubmed

      • NCCN task force report: management of neuropathy in cancer. J Natl Compr Canc Netw. 2009 Sep; 7 Suppl 5:S1-S26; quiz S27-8. View in: Pubmed

      • Case records of the Massachusetts General Hospital. Case 25-2009. A 36-year-old woman with hormone-receptor-positive breast cancer. N Engl J Med. 2009 Aug 13; 361(7):699-707. View in: Pubmed

      • Cancer-related direct-to-consumer advertising: awareness, perceptions, and reported impact among patients undergoing active cancer treatment. J Clin Oncol. 2009 Sep 01; 27(25):4182-7. View in: Pubmed

      • Third consensus on medical treatment of metastatic breast cancer. Ann Oncol. 2009 Nov; 20(11):1771-85. View in: Pubmed

      • Quality measures, clinical practice, NCCN, and McAllen, Texas. J Natl Compr Canc Netw. 2009 Jul; 7(7):695. View in: Pubmed

      • Personalizing treatment in early-stage breast cancer: The role of standard clinical factors and genomic information in adjuvant chemotherapy decision making. J Clin Oncol. 2009 May 20; 27(15_suppl):572. View in: Pubmed

      • Adjuvant chemotherapy in older women with early-stage breast cancer. N Engl J Med. 2009 May 14; 360(20):2055-65. View in: Pubmed

      • Do clinical trials belong in clinical guidelines? J Natl Compr Canc Netw. 2009 May; 7(5):489. View in: Pubmed

      • By the way, doctor. I've been having PET-CT scans to look for any growth or spread of previously removed tumors. Are they as reliable in detecting breast cancer as a regular mammogram? Harv Health Lett. 2009 May; 34(7):2. View in: Pubmed

      • SPIKES for difficult conversations with cancer patients. J Natl Compr Canc Netw. 2009 Apr; 7(4):341. View in: Pubmed

      • Tolerability of and adherence to combination oral therapy with gefitinib and capecitabine in metastatic breast cancer. Breast Cancer Res Treat. 2009 Oct; 117(3):615-23. View in: Pubmed

      • Breast cancer. Clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2009 Feb; 7(2):122-92. View in: Pubmed

      • Personalized medicine and breast cancer care. J Natl Compr Canc Netw. 2009 Feb; 7(2):109. View in: Pubmed

      • Single-agent lapatinib for HER2-overexpressing advanced or metastatic breast cancer that progressed on first- or second-line trastuzumab-containing regimens. Ann Oncol. 2009 Jun; 20(6):1026-31. View in: Pubmed

      • Circulating tumor cells in HER-2 positive metastatic breast cancer patients treated with trastuzumab and chemotherapy. Int J Biol Markers. 2009 Jan-Mar; 24(1):1-10. View in: Pubmed

      • AAV2/1-TNFR:Fc gene delivery prevents periodontal disease progression. Gene Ther. 2009 Mar; 16(3):426-36. View in: Pubmed

      • Updates in anti-HER2 combination therapy. Clin Adv Hematol Oncol. 2008 Dec; 6(12):873-4. View in: Pubmed

      • VEGF as a marker for outcome among advanced breast cancer patients receiving anti-VEGF therapy with bevacizumab and vinorelbine chemotherapy. Clin Cancer Res. 2008 Dec 01; 14(23):7871-7. View in: Pubmed

      • Self-reported practices and attitudes of US oncologists regarding off-protocol therapy. J Clin Oncol. 2008 Dec 20; 26(36):5994-6000. View in: Pubmed

      • Improving tolerance of AIs: predicting risk and uncovering mechanisms of musculoskeletal toxicity. Oncology (Williston Park). 2008 Nov 15; 22(12):1416, 1424. View in: Pubmed

      • Conflict of interest and oncology guidelines. J Natl Compr Canc Netw. 2008 Nov; 6(10):955. View in: Pubmed

      • Oncology teamwork. J Natl Compr Canc Netw. 2008 Sep; 6(8):715. View in: Pubmed

      • NCCN Task Force Report: mTOR inhibition in solid tumors. J Natl Compr Canc Netw. 2008 Sep; 6 Suppl 5:S1-20; quiz S21-2. View in: Pubmed

      • Lymphopenia associated with adjuvant anthracycline/ taxane regimens. Clin Breast Cancer. 2008 Aug; 8(4):352-6. View in: Pubmed

      • Breast surgery in stage IV breast cancer: impact of staging and patient selection on overall survival. Breast Cancer Res Treat. 2009 May; 115(1):7-12. View in: Pubmed

      • A randomized study of lapatinib alone or in combination with trastuzumab in heavily pretreated HER2+ metastatic breast cancer progressing on trastuzumab therapy. J Clin Oncol. 2008 May 20; 26(15_suppl):1015. View in: Pubmed

      • A pilot study of adjuvant bevacizumab and chemotherapy after neoadjuvant chemotherapy for high-risk breast cancer. J Clin Oncol. 2008 May 20; 26(15_suppl):519. View in: Pubmed

      • Cancer-related direct-to-consumer advertising: awareness, perceived impact, and associated patient and provider behavior. J Clin Oncol. 2008 May 20; 26(15_suppl):6631. View in: Pubmed

      • Pharmacogenomic variation of CYP2D6 and the choice of optimal adjuvant endocrine therapy for postmenopausal breast cancer: a modeling analysis. J Natl Cancer Inst. 2008 May 07; 100(9):642-8. View in: Pubmed

      • Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol. 2008 Apr 20; 26(12):1993-9. View in: Pubmed

      • Preoperative therapy as a model for translational research in breast cancer. Cancer Invest. 2008 Apr-May; 26(3):217-21. View in: Pubmed

      • Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840. J Clin Oncol. 2008 Apr 01; 26(10):1642-9. View in: Pubmed

      • Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol. 2008 Apr 10; 26(11):1810-6. View in: Pubmed

      • Weighing a dose-dense option for adjuvant chemotherapy and trastuzumab in early-stage breast cancer. J Clin Oncol. 2008 Mar 10; 26(8):1198-200. View in: Pubmed

      • A phase II study of lapatinib monotherapy in chemotherapy-refractory HER2-positive and HER2-negative advanced or metastatic breast cancer. Ann Oncol. 2008 Jun; 19(6):1068-74. View in: Pubmed

      • Preoperative therapy in invasive breast cancer: pathologic assessment and systemic therapy issues in operable disease. J Clin Oncol. 2008 Feb 10; 26(5):814-9. View in: Pubmed

      • Molecular origins of cancer. N Engl J Med. 2008 Jan 31; 358(5):527. View in: Pubmed

      • NCCN Task Force Report: breast cancer in the older woman. J Natl Compr Canc Netw. 2008; 6 Suppl 4:S1-25; quiz S26-7. View in: Pubmed

      • Aromatase inhibitors and arthralgias: a new frontier in symptom management for breast cancer survivors. J Clin Oncol. 2007 Sep 01; 25(25):3797-9. View in: Pubmed

      • Trastuzumab plus vinorelbine or taxane chemotherapy for HER2-overexpressing metastatic breast cancer: the trastuzumab and vinorelbine or taxane study. Cancer. 2007 Sep 01; 110(5):965-72. View in: Pubmed

      • Cognitive side-effects of adjuvant treatments. Breast. 2007 Dec; 16 Suppl 2:S166-8. View in: Pubmed

      • NCCN task force report: positron emission tomography (PET)/computed tomography (CT) scanning in cancer. J Natl Compr Canc Netw. 2007 May; 5 Suppl 1:S1-22; quiz S23-2. View in: Pubmed

      • Biological basis of breast cancer: an introduction. Semin Oncol. 2007 Apr; 34(2 Suppl 3):S1-3. View in: Pubmed

      • Chemotherapy for metastatic breast cancer. Hematol Oncol Clin North Am. 2007 Apr; 21(2):257-72. View in: Pubmed

      • Anemia in cancer: update on studies of erythropoiesis-stimulating agents. J Support Oncol. 2007 Apr; 5(4 Suppl 2):5-26. View in: Pubmed

      • Aromatase inhibitor-associated arthralgia syndrome. Breast. 2007 Jun; 16(3):223-34. View in: Pubmed

      • Phase II study of CT-2103 as first- or second-line chemotherapy in patients with metastatic breast cancer: unexpected incidence of hypersensitivity reactions. Invest New Drugs. 2007 Aug; 25(4):369-75. View in: Pubmed

      • Invasive breast cancer. J Natl Compr Canc Netw. 2007 Mar; 5(3):246-312. View in: Pubmed

      • Novel approaches to advanced breast cancer: bevacizumab and lapatinib. J Natl Compr Canc Netw. 2007 Mar; 5(3):314-23. View in: Pubmed

      • Predictors of resistance to preoperative trastuzumab and vinorelbine for HER2-positive early breast cancer. Clin Cancer Res. 2007 Feb 15; 13(4):1198-207. View in: Pubmed

      • Clinical trial update: implications and management of residual disease after neoadjuvant therapy for breast cancer. Breast Cancer Res. 2007; 9(5):110. View in: Pubmed

      • Myeloid growth factor support for dose-dense adjuvant chemotherapy for breast cancer. Oncology (Williston Park). 2006 Dec; 20(14 Suppl 9):13-5. View in: Pubmed

      • Pneumocystis carinii pneumonia during dose-dense chemotherapy for breast cancer. J Clin Oncol. 2006 Nov 20; 24(33):5330-1. View in: Pubmed

      • The role of angiogenesis inhibition in the treatment of breast cancer. Clin Adv Hematol Oncol. 2006 Oct; 4(10 Suppl 21):1-10; quiz 11-2. View in: Pubmed

      • Rebeccamycin analog for refractory breast cancer: a randomized phase II trial of dosing schedules. Invest New Drugs. 2007 Apr; 25(2):161-4. View in: Pubmed

      • Second consensus on medical treatment of metastatic breast cancer. Ann Oncol. 2007 Feb; 18(2):215-25. View in: Pubmed

      • HER2 testing in breast cancer: NCCN Task Force report and recommendations. J Natl Compr Canc Netw. 2006 Jul; 4 Suppl 3:S1-22; quiz S23-4. View in: Pubmed

      • Effect of treatment with sunitinib malate, a multitargeted tyrosine kinase inhibitor, on circulating plasma levels of VEGF, soluble VEGF receptors 2 and 3, and soluble KIT in patients with metastatic breast cancer. J Clin Oncol. 2006 Jun 20; 24(18_suppl):578. View in: Pubmed

      • Combination therapy with gefitinib and capecitabine in metastatic breast cancer (MBC): A phase I trial. J Clin Oncol. 2006 Jun 20; 24(18_suppl):10564. View in: Pubmed

      • Use of experimental therapy outside of clinical trials among U.S. oncologists. J Clin Oncol. 2006 Jun 20; 24(18_suppl):6047. View in: Pubmed

      • Trastuzumab and vinorelbine or taxane chemotherapy for HER2+ metastatic breast cancer: The TRAVIOTA study. J Clin Oncol. 2006 Jun 20; 24(18_suppl):650. View in: Pubmed

      • The impact of tumor progesterone receptor status on optimal adjuvant endocrine therapy for postmenopausal patients with early-stage breast cancer: a decision analysis. Cancer. 2006 Jun 15; 106(12):2576-82. View in: Pubmed

      • Inadvertent use of aromatase inhibitors in patients with breast cancer with residual ovarian function: cases and lessons. Clin Breast Cancer. 2006 Jun; 7(2):158-61. View in: Pubmed

      • NCCN Task Force Report: Adjuvant Therapy for Breast Cancer. J Natl Compr Canc Netw. 2006 Mar; 4 Suppl 1:S1-26. View in: Pubmed

      • Standards for follow-up care of patents with breast cancer. Breast. 2005 Dec; 14(6):500-8. View in: Pubmed

      • Efficacy of pegfilgrastim and darbepoetin alfa as hematopoietic support for dose-dense every-2-week adjuvant breast cancer chemotherapy. J Clin Oncol. 2005 Nov 20; 23(33):8340-7. View in: Pubmed

      • Prospective evaluation of concurrent paclitaxel and radiation therapy after adjuvant doxorubicin and cyclophosphamide chemotherapy for Stage II or III breast cancer. Int J Radiat Oncol Biol Phys. 2006 Feb 01; 64(2):496-504. View in: Pubmed

      • The distinctive nature of HER2-positive breast cancers. N Engl J Med. 2005 Oct 20; 353(16):1652-4. View in: Pubmed

      • American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer. J Clin Oncol. 2005 Oct 20; 23(30):7703-20. View in: Pubmed

      • Isolated central nervous system metastases in patients with HER2-overexpressing advanced breast cancer treated with first-line trastuzumab-based therapy. Ann Oncol. 2005 Nov; 16(11):1772-7. View in: Pubmed

      • Highlights of the American Society of Clinical Oncology annual meeting 2005. 13-17 May, 2005, Florida, USA. Expert Rev Anticancer Ther. 2005 Aug; 5(4):581-3. View in: Pubmed

      • Optimizing adjuvant endocrine therapy in postmenopausal women with early-stage breast cancer: a decision analysis. J Clin Oncol. 2005 Aug 01; 23(22):5178-87. View in: Pubmed

      • Phase II study of SU11248, a multitargeted receptor tyrosine kinase inhibitor (TKI), in patients (pts) with previously treated metastatic breast cancer (MBC). J Clin Oncol. 2005 Jun; 23(16_suppl):563. View in: Pubmed

      • Optimizing endocrine therapy in postmenopausal women with early stage breast cancer: A decision analysis for biological subsets of tumors. J Clin Oncol. 2005 Jun; 23(16_suppl):529. View in: Pubmed

      • Breast cancer. J Natl Compr Canc Netw. 2005 May; 3(3):238-89. View in: Pubmed

      • HER2 or not HER2: that is the question. J Clin Oncol. 2005 Jun 01; 23(16):3656-9. View in: Pubmed

      • American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. J Clin Oncol. 2005 Jan 20; 23(3):619-29. View in: Pubmed

      • American Society of Clinical Oncology Technology Assessment: chemotherapy sensitivity and resistance assays. J Clin Oncol. 2004 Sep 01; 22(17):3631-8. View in: Pubmed

      • Rebeccamycin analog for refractory breast cancer: a randomized phase II trial. J Clin Oncol. 2004 Jul 15; 22(14_suppl):547. View in: Pubmed

      • Phase II, 3-arm study of CCI-779 in combination with letrozole in postmenopausal women with locally advanced or metastatic breast cancer: preliminary results. J Clin Oncol. 2004 Jul 15; 22(14_suppl):544. View in: Pubmed

      • Ductal carcinoma in situ of the breast. N Engl J Med. 2004 Apr 01; 350(14):1430-41. View in: Pubmed

      • Trastuzumab regimens for HER2-overexpressing metastatic breast cancer. Clin Breast Cancer. 2003 Dec; 4(5):329-37; discussion 338-9. View in: Pubmed

      • Follow-up care of breast cancer survivors. Semin Oncol. 2003 Dec; 30(6):817-25. View in: Pubmed

      • Beyond tamoxifen--extending endocrine treatment for early-stage breast cancer. N Engl J Med. 2003 Nov 06; 349(19):1857-9. View in: Pubmed

      • Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm. J Clin Oncol. 2003 Aug 01; 21(15):2889-95. View in: Pubmed

      • Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma. Cancer. 2003 Jun 15; 97(12):2972-7. View in: Pubmed

      • Use of the peroxisome proliferator-activated receptor (PPAR) gamma ligand troglitazone as treatment for refractory breast cancer: a phase II study. Breast Cancer Res Treat. 2003 Jun; 79(3):391-7. View in: Pubmed

      • American Society of Clinical Oncology technology assessment working group update: use of aromatase inhibitors in the adjuvant setting. J Clin Oncol. 2003 Jul 01; 21(13):2597-9. View in: Pubmed

      • Quality of non-breast cancer health maintenance among elderly breast cancer survivors. J Clin Oncol. 2003 Apr 15; 21(8):1447-51. View in: Pubmed

      • Do patients participating in clinical trials want to know study results? J Natl Cancer Inst. 2003 Mar 19; 95(6):491-2. View in: Pubmed

      • Preoperative therapy with trastuzumab and paclitaxel followed by sequential adjuvant doxorubicin/cyclophosphamide for HER2 overexpressing stage II or III breast cancer: a pilot study. J Clin Oncol. 2003 Jan 01; 21(1):46-53. View in: Pubmed

      • American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for women with hormone receptor-positive breast cancer: status report 2002. J Clin Oncol. 2002 Aug 01; 20(15):3317-27. View in: Pubmed

      • American Society of Clinical Oncology technology assessment of pharmacologic interventions for breast cancer risk reduction including tamoxifen, raloxifene, and aromatase inhibition. J Clin Oncol. 2002 Aug 01; 20(15):3328-43. View in: Pubmed

      • Gemcitabine-induced radiation recall. Int J Radiat Oncol Biol Phys. 2002 Jun 01; 53(2):394-400. View in: Pubmed

      • HER2 overexpressing metastatic breast cancer. Curr Treat Options Oncol. 2002 Apr; 3(2):163-74. View in: Pubmed

      • Treatment of breast cancer during pregnancy. Expert Opin Pharmacother. 2002 Apr; 3(4):423-8. View in: Pubmed

      • New cytotoxic agents and schedules for advanced breast cancer. Semin Oncol. 2001 Aug; 28(4):344-58. View in: Pubmed

      • Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer. J Clin Oncol. 2001 May 15; 19(10):2722-30. View in: Pubmed

      • Unusual aspects of breast cancer: case 2. Synchronous bilateral lung and breast cancers. J Clin Oncol. 2001 May 01; 19(9):2571-3. View in: Pubmed

      • Side effects of chemotherapy and combined chemohormonal therapy in women with early-stage breast cancer. J Natl Cancer Inst Monogr. 2001; (30):135-42. View in: Pubmed

      • New combinations with Herceptin in metastatic breast cancer. Oncology. 2001; 61 Suppl 2:50-7. View in: Pubmed

      • Primary care for survivors of breast cancer. N Engl J Med. 2000 Oct 12; 343(15):1086-94. View in: Pubmed

      • Discussing complementary therapies with cancer patients: what should we be talking about? J Clin Oncol. 2000 Jul; 18(13):2501-4. View in: Pubmed

      • Docetaxel administered on a weekly basis for metastatic breast cancer. J Clin Oncol. 2000 Mar; 18(6):1212-9. View in: Pubmed

      • Side effects of chemotherapy. Case 1. Radiation recall dermatitis from gemcitabine. J Clin Oncol. 2000 Feb; 18(3):693-4. View in: Pubmed

      • Phase I study of Doxil and vinorelbine in metastatic breast cancer. Ann Oncol. 1999 Sep; 10(9):1113-6. View in: Pubmed

      • Use of alternative medicine by women with early-stage breast cancer. N Engl J Med. 1999 Jun 03; 340(22):1733-9. View in: Pubmed

      • Hypertrophic osteoarthropathy. J Clin Oncol. 1997 Jul; 15(7):2759-60. View in: Pubmed

      • Identification of amino acid residues of the retroviral aspartic proteinases important for substrate specificity and catalytic efficiency. Adv Exp Med Biol. 1995; 362:399-406. View in: Pubmed

      • Mutational analysis of the substrate binding pockets of the Rous sarcoma virus and human immunodeficiency virus-1 proteases. J Biol Chem. 1994 Apr 15; 269(15):11170-7. View in: Pubmed

      • Determinants of helper T cell-dependent antibody production. Semin Immunol. 1993 Dec; 5(6):441-7. View in: Pubmed

      • In vivo role of interleukin 4 in T cell tolerance induced by aqueous protein antigen. J Exp Med. 1993 Feb 01; 177(2):457-63. View in: Pubmed

      • Proteolysis in the maturation of avian retroviruses does not require calcium. Virology. 1992 Aug; 189(2):771-4. View in: Pubmed

      • Aqueous antigens induce in vivo tolerance selectively in IL-2- and IFN-gamma-producing (Th1) cells. J Immunol. 1992 Jun 15; 148(12):3687-91. View in: Pubmed

      • Mutations that alter the activity of the Rous sarcoma virus protease. J Biol Chem. 1992 May 15; 267(14):9481-90. View in: Pubmed

      • Analysis of substrate interactions of the Rous sarcoma virus wild type and mutant proteases and human immunodeficiency virus-1 protease using a set of systematically altered peptide substrates. J Biol Chem. 1992 May 15; 267(14):9491-8. View in: Pubmed

      • Processing of avian retroviral gag polyprotein precursors is blocked by a mutation at the NC-PR cleavage site. J Virol. 1992 Mar; 66(3):1781-5. View in: Pubmed

      • Assembly and processing of avian retroviral gag polyproteins containing linked protease dimers. J Virol. 1991 Nov; 65(11):6165-72. View in: Pubmed

      • Humoral immune functions in IL-4 transgenic mice. J Immunol. 1991 Nov 01; 147(9):2950-6. View in: Pubmed

      • Activation and functions of CD4+ T-cell subsets. Immunol Rev. 1991 Oct; 123:5-22. View in: Pubmed

      • T-cell-mediated activation of B cells. Curr Opin Immunol. 1991 Jun; 3(3):345-9. View in: Pubmed

      • Functional phospholipid/sphingomyelin ratio: an easy to interpret indicator of fetal lung maturity. Ann Clin Lab Sci. 1986 Sep-Oct; 16(5):407-11. View in: Pubmed

      • Degree of unsaturation of the fatty acid chains of phospholipids influences the fluorescence polarization: implications for evaluating fetal lung maturity. Clin Chem. 1986 Mar; 32(3):425-8. View in: Pubmed

      • MAMMARY PAGET'S DISEASE. Skin (Los Angeles). 1964 Jul; 3:206-11. View in: Pubmed

      Locations

      Location Avtar

      Dana-Farber Cancer Institute - Chestnut Hill

      300 Boylston Street Newton, MA 02459
      Get Directions

      Dana-Farber Cancer Institute - Chestnut Hill

      Location Avtar

      Dana-Farber Cancer Institute - Chestnut Hill

      300 Boylston Street Newton, MA 02459
      Get Direction
      42.3192, -71.1798

      Ratings and Comments

      Harold J. Burstein, MD, PhD

      About Our Ratings

      Physician Star Rating Comment Block

      Discovery and Insights